These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study. Herrera L; Leal I; Lapi F; Schuemie M; Arcoraci V; Cipriani F; Sessa E; Vaccheri A; Piccinni C; Staniscia T; Vestri A; Di Bari M; Corrao G; Zambon A; Gregori D; Carle F; Sturkenboom M; Mazzaglia G; Trifiro G Osteoporos Int; 2015 May; 26(5):1499-506. PubMed ID: 25752621 [TBL] [Abstract][Full Text] [Related]
3. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. Sørensen HT; Christensen S; Mehnert F; Pedersen L; Chapurlat RD; Cummings SR; Baron JA BMJ; 2008 Apr; 336(7648):813-6. PubMed ID: 18334527 [TBL] [Abstract][Full Text] [Related]
4. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study. Lamberg AL; Horvath-Puho E; Christensen S; Sørensen HT Osteoporos Int; 2010 Nov; 21(11):1911-7. PubMed ID: 19997902 [TBL] [Abstract][Full Text] [Related]
5. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study. Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678 [TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Loke YK; Jeevanantham V; Singh S Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379 [TBL] [Abstract][Full Text] [Related]
7. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. Wilkinson GS; Baillargeon J; Kuo YF; Freeman JL; Goodwin JS J Clin Oncol; 2010 Nov; 28(33):4898-905. PubMed ID: 20940190 [TBL] [Abstract][Full Text] [Related]
8. Oral Bisphosphonate use Reduces Cardiovascular Events in a Cohort of Danish Patients Referred for Bone Mineral Density. Rodríguez AJ; Ernst MT; Nybo M; Prieto-Alhambra D; Ebeling PR; Hermann AP; Abrahamsen B J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32717068 [TBL] [Abstract][Full Text] [Related]
9. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study. Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M; Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594 [TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate therapy start may transiently increase the risk of tendon rupture in patients with glucocorticoid co-medication: a population-based observational study. Spoendlin J; Meier C; Jick SS; Meier CR Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1116-1123. PubMed ID: 27297005 [TBL] [Abstract][Full Text] [Related]
11. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis. Sharma A; Chatterjee S; Arbab-Zadeh A; Goyal S; Lichstein E; Ghosh J; Aikat S Chest; 2013 Oct; 144(4):1311-1322. PubMed ID: 23722644 [TBL] [Abstract][Full Text] [Related]
12. Saving bones without risking brain-bisphosphonates and risk of stroke: matched case-control study. Asghar ZB; Godoy Caballero A; Pathirannehelage S; Williams J; McKay S; Grassby P; de Lusignan S; Niroshan Siriwardena A Osteoporos Int; 2019 Sep; 30(9):1845-1854. PubMed ID: 31214750 [TBL] [Abstract][Full Text] [Related]
13. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis. Rhee CW; Lee J; Oh S; Choi NK; Park BJ Osteoporos Int; 2012 Jan; 23(1):247-54. PubMed ID: 21431993 [TBL] [Abstract][Full Text] [Related]
14. Atrial fibrillation in fracture patients treated with oral bisphosphonates. Abrahamsen B; Eiken P; Brixen K J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097 [TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates and risk of cardiovascular events: a meta-analysis. Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398 [TBL] [Abstract][Full Text] [Related]
16. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. Christiansen CF; Christensen S; Mehnert F; Cummings SR; Chapurlat RD; Sørensen HT Arch Intern Med; 2009 Oct; 169(18):1677-83. PubMed ID: 19822824 [TBL] [Abstract][Full Text] [Related]
17. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker. Pazianas M; Blumentals WA; Miller PD Osteoporos Int; 2008 Jun; 19(6):773-9. PubMed ID: 17999023 [TBL] [Abstract][Full Text] [Related]
18. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. Erichsen R; Christiansen CF; Frøslev T; Jacobsen J; Sørensen HT Br J Cancer; 2011 Sep; 105(7):881-3. PubMed ID: 21878939 [TBL] [Abstract][Full Text] [Related]
19. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study. Etminan M; Aminzadeh K; Matthew IR; Brophy JM J Rheumatol; 2008 Apr; 35(4):691-5. PubMed ID: 18203310 [TBL] [Abstract][Full Text] [Related]
20. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. Grosso A; Douglas I; Hingorani A; MacAllister R; Smeeth L PLoS One; 2009; 4(3):e4720. PubMed ID: 19266096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]